UMMS Affiliation

Department of Medicine, Division of Hematology Oncology; Department of Pathology

Publication Date

2021-07-09

Document Type

Article

Disciplines

Hematology | Hemic and Lymphatic Diseases | Neoplasms | Oncology

Abstract

In summary, we show rapid and deep remission induced by blinatumomab in CD19(+) blast phase CML. Clinicians may consider the use of bispecific T-cell engager therapy as a bridge to transplant. Additional studies are needed before expanding the US Food and Drug Administration indication of blinatumomab to include lymphoid blast phase CML.

Keywords

Chronic myeloid leukemia

Rights and Permissions

Copyright © 2021 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

DOI of Published Version

10.1200/PO.21.00039

Source

Patel SA, Bledsoe JR, Higgins AW, Hutchinson L, Gerber JM. Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase. JCO Precis Oncol. 2021 Jul 9;5:PO.21.00039. doi: 10.1200/PO.21.00039. PMID: 34409243; PMCID: PMC8367045. Link to article on publisher's site

Journal/Book/Conference Title

JCO precision oncology

Related Resources

Link to Article in PubMed

PubMed ID

34409243

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS